NASDAQ:ARAVAravive Stock Price, Forecast & News

Aravive's stock was trading at $4.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARAV stock has increased by 160.7% and is now trading at $13.01. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive.

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aravive.

Aravive Inc (NASDAQ:ARAV) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.36. View Aravive's earnings history.

5 Wall Street analysts have issued 12 month price targets for Aravive's stock. Their forecasts range from $15.00 to $31.00. On average, they expect Aravive's stock price to reach $26.00 in the next year. This suggests a possible upside of 99.8% from the stock's current price. View analysts' price targets for Aravive.

Headlines about ARAV stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aravive earned a news impact score of 1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutAravive.

Aravive saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 604,900 shares, a decrease of 9.8% from the April 30th total of 670,800 shares. Based on an average daily trading volume, of 173,500 shares, the days-to-cover ratio is presently 3.5 days. Currently, 7.1% of the shares of the stock are sold short. View Aravive's Current Options Chain.

Some companies that are related to Aravive include Omeros (OMER), Gossamer Bio (GOSS), Cue Biopharma (CUE), Arcturus Therapeutics (ARCT), Kura Oncology (KURA), Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Eagle Pharmaceuticals (EGRX), Kadmon (KDMN), Molecular Templates (MTEM), Dynavax Technologies (DVAX), Retrophin (RTRX), Kala Pharmaceuticals (KALA) and G1 Therapeutics (GTHX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Applied Genetic Technologies (AGTC), Ardelyx (ARDX), Bank of America (BAC), Clovis Oncology (CLVS), Precision BioSciences (DTIL), Galmed Pharmaceuticals (GLMD), Inovio Pharmaceuticals (INO) and Myovant Sciences (MYOV).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Aravive's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.34%), Two Sigma Advisers LP (1.01%), Alpine Global Management LLC (1.03%), Two Sigma Investments LP (0.80%), Geode Capital Management LLC (0.55%) and UBS Group AG (0.53%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju. View institutional ownership trends for Aravive.

ARAV stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., Morgan Stanley, and UBS Group AG. View insider buying and selling activity for Aravive.

ARAV stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Alpine Global Management LLC, Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, Invesco Ltd., Wedbush Securities Inc., Jane Street Group LLC, and Acadian Asset Management LLC. View insider buying and selling activity for Aravive.

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAV stock can currently be purchased for approximately $13.01.

Aravive has a market capitalization of $207.50 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

The official website for Aravive is www.aravive.com.

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]